Catherine Moukheibir - Jul 3, 2025 Form 4 Insider Report for MoonLake Immunotherapeutics (MLTX)

Role
Director
Signature
/s/ Matthias Bodenstedt, Attorney-in-fact for Catherine Moukheibir
Stock symbol
MLTX
Transactions as of
Jul 3, 2025
Transactions value $
-$1,146,565
Form type
4
Date filed
7/7/2025, 04:03 PM
Previous filing
Jun 12, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Moukheibir Catherine Director C/O MOONLAKE IMMUNOTHERAPEUTICS, DORFSTRASSE 29, ZUG, SWITZERLAND /s/ Matthias Bodenstedt, Attorney-in-fact for Catherine Moukheibir 2025-07-07 0001772130

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MLTX Class A ordinary shares, par value $0.0001 per share Options Exercise $0 +23.5K $0.00 23.5K Jul 3, 2025 Direct
transaction MLTX Class A ordinary shares, par value $0.0001 per share Sale -$1.15M -23.5K -100% $48.79 0 Jul 3, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MLTX Option to Buy Options Exercise $0 -23.5K -52.22% $0.00 21.5K Jul 3, 2025 Class A ordinary shares, par value $0.0001 per share 23.5K $12.25 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $48.59 to $49.01. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F2 These options are fully vested.